HC Wainwright Issues Positive Estimate for Agenus Earnings

Agenus Inc. (NASDAQ:AGEN) – Equities researchers at HC Wainwright raised their Q2 2026 EPS estimates for shares of Agenus in a research report issued on Tuesday, May 12th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will post earnings per share of $0.06 for the quarter, up from their prior forecast of ($0.32). The consensus estimate for Agenus’ current full-year earnings is $2.10 per share. HC Wainwright also issued estimates for Agenus’ Q3 2026 earnings at $0.05 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at $1.07 EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at ($0.56) EPS, FY2029 earnings at ($0.34) EPS and FY2030 earnings at $0.09 EPS.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Monday, May 11th. The biotechnology company reported $1.02 earnings per share for the quarter, missing analysts’ consensus estimates of $2.10 by ($1.08). Agenus had a net margin of 50.49% and a negative return on equity of 31.66%. The firm had revenue of $33.70 million for the quarter, compared to the consensus estimate of $129.50 million.

AGEN has been the subject of several other reports. Zacks Research cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday. Wall Street Zen raised Agenus from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $14.50.

Agenus Price Performance

Shares of NASDAQ:AGEN opened at $3.47 on Thursday. Agenus has a 1 year low of $2.71 and a 1 year high of $7.34. The business has a 50 day simple moving average of $3.72 and a two-hundred day simple moving average of $3.66. The firm has a market capitalization of $144.49 million, a PE ratio of 2.18 and a beta of 1.60.

Institutional Trading of Agenus

Several large investors have recently bought and sold shares of AGEN. EP Wealth Advisors LLC purchased a new stake in Agenus during the 4th quarter worth approximately $31,000. R Squared Ltd purchased a new stake in Agenus during the 4th quarter worth approximately $41,000. Redwood Family Wealth LLC purchased a new stake in Agenus during the 4th quarter worth approximately $44,000. Traynor Capital Management Inc. purchased a new stake in Agenus during the 3rd quarter worth approximately $50,000. Finally, Quadrature Capital Ltd purchased a new stake in Agenus during the 4th quarter worth approximately $54,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Key Agenus News

Here are the key news stories impacting Agenus this week:

• Positive Sentiment: HC Wainwright raised its FY2027 earnings estimate for Agenus, suggesting a better medium-term profit outlook than previously expected.
• Positive Sentiment: HC Wainwright also increased FY2028, FY2029 and FY2030 EPS estimates, indicating improving expectations further out.
• Positive Sentiment: The firm lifted its Q2 2026 EPS forecast, showing some near-term improvement versus prior estimates.
• Neutral Sentiment: HC Wainwright cut its Q3 and Q4 2026 EPS estimates, reflecting a more cautious view on results later this year.
• Neutral Sentiment: HC Wainwright reduced its FY2026 EPS estimate, implying a lower full-year profit outlook even though the stock already trades at a low valuation.
• Negative Sentiment: Zacks Research downgraded Agenus from strong-buy to hold, which likely weighed on investor sentiment.
• Negative Sentiment: The company’s recent earnings report missed expectations, with Q1 EPS and revenue both coming in well below consensus, reinforcing concerns about execution.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.